Argenx announces european commission approval of vyvgart subcutaneous injection for chronic inflammatory demyelinating polyneuropathy

Vyvgart ® sc, first-and-only igg fc-antibody fragment which specifically targets the neonatal fc receptor (fcrn), now approved for use in europe for cidp approval based on adhere clinical trial, the largest study of cidp patients to date first novel mechanism of action for cidp treatment in more than 30 years june 20, 2025, 7:00 pm cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the european commission (ec) approved vyvgart® (efgartigimod alfa) 1000mg for subcutaneous (sc) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (cidp) after prior treatment with corticosteroids or immunoglobulins. vyvgart for sc injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional.
ARGX Ratings Summary
ARGX Quant Ranking